Diagnosis and treatment of CD20 negative B cell lymphomas

被引：25
|
作者：
Katchi, Tasleem
Liu, Delong [1 ]
机构：
[1] New York Med Coll, Div Hematol & Oncol, Valhalla, NY 10595 USA
来源：
BIOMARKER RESEARCH | 2017年 / 5卷
关键词：
DOSE-ADJUSTED EPOCH; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; BRUTON TYROSINE KINASE; CODOX-M/IVAC; BURKITT-LYMPHOMA; PHASE-II; HODGKINS-LYMPHOMA; POOR-PROGNOSIS; FOLLOW-UP;
D O I：
10.1186/s40364-017-0088-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CD20 negative B cell non-Hodgkin lymphoma (NHL) is rare and accounts for approximately 1-2% of B cell lymphomas. CD20-negative NHL is frequently associated with extranodal involvement, atypical morphology, aggressive clinical behaviour, resistance to standard chemotherapy and poor prognosis. The most common types of these include plasmablastic lymphoma, primary effusion lymphoma, large B-cell lymphoma arising from HHV8-associated multicentric Castleman's disease, and ALK+ large B cell lymphoma. This review provides an overview of the diagnostic and treatment modalities for CD20 negative B cell NHL.
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Treatment of CD20+ B-cell cutaneous lymphomas using intralesional rituximab
    Marco, Ardigo
    de Felice, Catia
    Berardesca, Enzo
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 60 (03) : AB7 - AB7
  • [42] Loss of CD20 expression in relapsed lymphomas after rituximab therapy
    Haidar, JH
    Shamseddine, A
    Salem, Z
    Mrad, YA
    Nasr, MR
    Zaatari, G
    Bazarbachi, A
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2003, 70 (05) : 330 - 332
  • [43] CD20
    Warzynski, MJ
    Graham, DM
    Axtell, RA
    Zakem, MH
    Rotman, RK
    APPLIED IMMUNOHISTOCHEMISTRY, 1996, 4 (03): : 218 - 218
  • [44] CD20
    Macardle, PJ
    Nicholson, IC
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2002, 16 (02): : 136 - 138
  • [45] Comparison of biodistributions and therapeutic efficacies of pretargeted radioimmunoconjugates targeting the CD20, CD22, and DR molecules on human B cell lymphomas.
    Pantelias, A
    Pagel, JM
    Hedin, N
    Lin, Y
    Axworthy, D
    Theodore, LJ
    Press, OW
    BLOOD, 2005, 106 (11) : 181A - 182A
  • [46] Comparative Assessment of Surface CD19 and CD20 Expression on B-Cell Lymphomas from Clinical Biopsies: Implications for Targeted Therapies
    Horna, Pedro
    Nowakowski, Grzegorz
    Endell, Jan
    Boxhammer, Rainer
    BLOOD, 2019, 134
  • [47] Bright CD38 and Dim CD20 by Flow Cytometry May Predict for Double Hit Lymphomas in MYC Rearranged High-Grade B-Cell Lymphomas
    Willis, J. S.
    Seegmiller, A. C.
    Uddin, N.
    Karandikar, N. J.
    Chen, W.
    MODERN PATHOLOGY, 2011, 24 : 329A - 329A
  • [48] Bright CD38 and Dim CD20 by Flow Cytometry May Predict for Double Hit Lymphomas in MYC Rearranged High-Grade B-Cell Lymphomas
    Willis, J. S.
    Seegmiller, A. C.
    Uddin, N.
    Karandikar, N. J.
    Chen, W.
    LABORATORY INVESTIGATION, 2011, 91 : 329A - 329A
  • [49] CD19/CD20 bispecific chimeric antigen receptor (CAR) in naive/memory T-cells for the treatment of relapsed or refractory B-cell lymphomas.
    Ghafouri, Sanaz Noelle
    Walthers, Christopher
    Roshandell, Mobina
    Ji, Brenda
    Trent, Jacqueline
    Chen, Jia Ming
    Naparstek, Jacob
    Harris, Caitlin
    Schweppe, Thomas
    Nawaly, Karla K.
    Mead, Monica
    de Vos, Sven
    Young, Patricia
    Oliai, Caspian
    Schiller, Gary
    Timmerman, John M.
    Chen, Yvonne Y.
    Larson, Sarah
    CANCER RESEARCH, 2021, 81 (13)
  • [50] CD20-Negative Large B-Cell Lymphomas: Analysis of the National Cancer Data Base
    Qunaj, Lindor
    Castillo, Jorge J.
    Olszewski, Adam J.
    BLOOD, 2016, 128 (22)
12345